Drug Type Monoclonal antibody |
Synonyms Anti-GITR monoclonal antibody, Anti-GITR-mAB, Anti-TNFRSF18 monoclonal antibody + [3] |
Target |
Action agonists |
Mechanism GITR agonists(Glucocorticoid-induced tumor necrosis factor receptor-related protein agonists) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Castration-Resistant Prostatic Cancer | Phase 3 | United States | 20 May 2019 | |
Platinum-Resistant Ovarian Carcinoma | Phase 3 | United States | 20 May 2019 | |
Advanced Malignant Solid Neoplasm | Phase 3 | United States | 01 Jan 2016 | |
Unresectable Melanoma | Phase 3 | United States | 01 Oct 2010 | |
Breast Cancer | Phase 2 | - | - | |
Breast Cancer | Phase 2 | - | - | |
Ovarian Cancer | Phase 2 | - | - | |
Ovarian Cancer | Phase 2 | - | - | |
Prostatic Cancer | Phase 2 | - | - | |
Prostatic Cancer | Phase 2 | - | - |
Phase 1 | 26 | (swqlcrkzhw) = none czyvxzyaim (jntuxdtwxp ) View more | Positive | 14 Dec 2018 |